|
Friday, November 17, 2017
Print Current Session:
 |
|
|
Friday
SESSION 85:
PROGRESS IN THE MEDICAL TREATMENTS OF VASCULAR DISEASE; VASCULAR DISEASES AND RISK PREDICTION
|
|
| SESSION 85 SCHEDULE | |
| 2:07 PM - 2:12 PM | Why ACE Inhibitors And Angiotension Receptor Blockers Should Be Stopped 24 Hours Before Vascular Surgery And What Is Optimal Antiplatelet Drug Therapy In Vascular Patients: Based On The EUCLID Trial |
|
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Caron B. Rockman, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:13 PM - 2:18 PM | Cilostazol Improves Outcomes After Lower Extremity Endo And Open Procedures: When And How Should It Be Used |
|
Presenter(s):Anthony J. Comerota, MD, FACS, FACC Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:19 PM - 2:24 PM | New Developments In Troponin Testing: What Is Its Value As A Risk Predictor In Patients Undergoing Endo And Open Vascular Procedures: Value Of New High Sensitivity Troponin Assay |
|
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Caron B. Rockman, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:25 PM - 2:30 PM | Which Patients Should Receive Primary Prevention Lipid Lowering Statin Therapy: What Drug And Dose: How Do The HOPE 3 Trial Findings Help |
|
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:31 PM - 2:36 PM | How Do PCSK-9 Inhibitors Work: When And How Should They Currently Be Used: Advantages And Limitations |
|
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:37 PM - 2:42 PM | Importance Of Tight Glucose Control To Minimize Neurological Complications Of Branched Endografts For TAAAs And TEVAR |
|
Presenter(s):Jade S. Hiramoto, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:43 PM - 2:48 PM | Smoking Cessation In Vascular Surgery Patients: How Well Do Drugs And Interventions Work And How To Make Them Work Better: From The VAPOR Trial |
|
Presenter(s):Philip P. Goodney, MD, MS Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:49 PM - 2:54 PM | New Biomarkers (Advanced Glycation End Product) To Identify High Risk Vascular Patients Who Need Intensified Lipid Lowering Treatment |
|
Presenter(s):Clark J. Zeebregts, MD, PhD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 2:55 PM - 3:00 PM | Segmental Arterial Mediolysis: What Is It: How To Diagnose And Treat It |
|
Presenter(s):Samuel R. Money, MD, MBA Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 3:01 PM - 3:06 PM | 8 Markers Or Indicators To Make One Look For Asymptomatic Thoracic Aneurysm Disease |
|
Presenter(s):John A. Elefteriades, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 3:07 PM - 3:12 PM | Does Raising HDL-Cholesterol (HDL-C) Levels Help To Prevent Cardiovascular Events In High Risk Patients: New Results From Recent HDL-Raising Trials |
|
Presenter(s):Richard Bulbulia, MA, MD, FRCS Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 3:13 PM - 3:25 PM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 85 | |
| previous | next |